WU-NK-101 in Relapsed/Refractory AML and MDS

A Phase 2 Study of WU-NK-101 in Relapsed/Refractory AML and MDS

This is a phase 2 study with a lead-in cohort of WU-NK-101, a cytokine-induced memory-like NK cell product derived from leukapheresed allogeneic donor NK cells activated ex vivo using HCW-9201, a GMP-grade fusion cytokine comprising IL-12, IL-15, and IL-18. Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will receive lymphodepleting chemotherapy (Flu/Cy) and two infusions of WU-NK-101 at the previously defined maximum tolerated dose (MTD), fourteen days apart. Low dose rhIL-2 will be administered to patients for in vivo expansion following cell infusion. Patients will be assessed for anti-leukemic efficacy and safety. Re-infusion of patients who relapsed after clinical response will be considered.

WU-NK-101 in Relapsed/Refractory AML and MDS

Recruitment

Summary

Participation Requirements

Description

Tracking Information